Neuroone Medical Technologies (NMTC) Equity Average (2011 - 2026)

Neuroone Medical Technologies has disclosed Equity Average across 15 years of filings, most recently posting $5.7 million for Q1 2026.

• Quarterly Equity Average rose 182.66% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (up 182.66% YoY) and the FY2025 annual result came in at $3.9 million, up 11.64% from the prior year.
• Equity Average slipped to $5.7 million in Q1 2026, from $6.7 million in the prior quarter.
• Across five years, Equity Average topped out at $14.5 million in Q1 2022 and bottomed at $1.9 million in Q4 2024.
• The 5-year median for Equity Average is $5.3 million (2023), against an average of $6.2 million.
• Year-over-year, Equity Average tumbled 64.78% in 2024 and soared 297.78% in 2025.
• Neuroone Medical Technologies' Equity Average stood at $8.9 million in 2022, then tumbled by 39.99% to $5.3 million in 2023, then tumbled by 64.78% to $1.9 million in 2024, then jumped by 258.62% to $6.7 million in 2025, then fell by 14.81% to $5.7 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $5.7 million, $6.7 million, and $7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.